About Voltage-dependent calcium channel gamma-3 subunit
Voltage-dependent calcium channel gamma-3 subunit (CACNG3) is a protein
from Homo sapiens identified by UniProt accession
O60359, 315 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | Voltage-dependent calcium channel gamma-3 subunit |
|---|
| UniProt accession | O60359 |
|---|
| Gene | CACNG3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 315 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (53)
Diseases linked to this target (Open Targets).
- cardiovascular disease · score 0.46
- generalized anxiety disorder · score 0.39
- gastrointestinal disease · score 0.37
- Polyuria · score 0.37
- Urinary incontinence · score 0.37
- body mass index · score 0.33
- anxiety · score 0.27
- breast adenocarcinoma · score 0.25
- endometrial cancer · score 0.20
- lymphocyte count · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O60359-F1 | alphafold | PREDICTED | 68.10 | — |
Amino-acid sequence (315 residues)
MRMCDRGIQM LITTVGAFAA FSLMTIAVGT DYWLYSRGVC RTKSTSDNET SRKNEEVMTH SGLWRTCCLE GAFRGVCKKI DHFPEDADYE QDTAEYLLRA VRASSVFPIL SVTLLFFGGL CVAASEFHRS RHNVILSAGI FFVSAGLSNI IGIIVYISAN AGDPGQRDSK KSYSYGWSFY FGAFSFIIAE IVGVVAVHIY IEKHQQLRAK SHSEFLKKST FARLPPYRYR FRRRSSSRST EPRSRDLSPI SKGFHTIPST DISMFTLSRD PSKITMGTLL NSDRDHAFLQ FHNSTPKEFK ESLHNNPANR RTTPV
Explore Voltage-dependent calcium channel gamma-3 subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets